However, different randomized studies assessing the combination of ibrutinib [35], lenalidomide [36], or bortezomib [37,38] with R-CHOP did not demonstrate a clear benefit over R-CHOP alone, failing to confirm the potential advantage of this strategy, even though these studies were directed toward non-GCB patients by IHC [35] or ABC patients identified by GEP (Table 1) In the REMoDL-B, although there was no restriction according to COO, outcomes were analyzed according to COO by GEP, with no clear benefit when the analysis was restricted to the ABC patients [37]. The gene discussed is DDIT3; the disease is aneurysmal bone cyst.